HEALTH CARE
 [%ETwY%] [%rGOX%] [%PQtc%] [%UMNJ%] 
Research by RHB
Overweight (Maintained)

“A Decent Showing; Still OVERWEIGHT”

We expect demand for private healthcare to be underpinned by encouraging growth from medical tourists, a growing number of non-communicable diseases (NCD), and ageing society trends. While the healthcare sector generally has defensive attributes, we continue to advocate for investors to lean towards domestic-centric names as these provide better earnings stability.

Analyst(s):
Oong Chun Sung
[%NOav%]

HEALTH CARE
 $KLSE-IHH $KLSE-KPJ $KLSE-DPHARMA $KLSE-KOTRA 
Research by RHB
Overweight (Maintained)

“A Decent Showing; Still OVERWEIGHT”

We expect demand for private healthcare to be underpinned by encouraging growth from medical tourists, a growing number of non-communicable diseases (NCD), and ageing society trends. While the healthcare sector generally has defensive attributes, we continue to advocate for investors to lean towards domestic-centric names as these provide better earnings stability.

Analyst(s):
Oong Chun Sung
chun.sung@rhbgroup.com

$DPHARMA / 7148 (DUOPHARMA BIOTECH BERHAD)